US FDA approves expanded indication for AbbVie’s oral migraine therapy
Pharmaceutical Technology
APRIL 18, 2023
The medication has become the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist to receive approval for preventing episodic and chronic migraine. Qulipta received approval to treat migraine across frequencies, including both episodic and chronic.
Let's personalize your content